Kolaja KL - Search Results

1

HPLC-MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium.

Geenen S, Guallar-Hoyas C, Michopoulos F, Kenna JG, Kolaja KL, Westerhoff HV, Thomas P, Wilson ID. Geenen S, et al. Among authors: kolaja kl. J Pharm Biomed Anal. 2011 Nov 1;56(3):655-63. doi: 10.1016/j.jpba.2011.06.001. Epub 2011 Jun 13. J Pharm Biomed Anal. 2011. PMID: 21752568

2

HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium.

Geenen S, Michopoulos F, Kenna JG, Kolaja KL, Westerhoff HV, Wilson I. Geenen S, et al. Among authors: kolaja kl. J Pharm Biomed Anal. 2011 Apr 5;54(5):1128-35. doi: 10.1016/j.jpba.2010.11.038. Epub 2010 Dec 2. J Pharm Biomed Anal. 2011. PMID: 21176868

3

Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product.

Mora J, Forman D, Hu J, Ijantkar A, Gokemeijer J, Kolaja KL, Picarillo C, Jawa V, Yue H, Lamy J, Denies S, Schockaert J, Ackaert C. Mora J, et al. Among authors: kolaja kl. J Pharm Sci. 2024 Aug;113(8):2151-2160. doi: 10.1016/j.xphs.2024.05.018. Epub 2024 May 18. J Pharm Sci. 2024. PMID: 38768755

4

Investigation Into the Role of ERK in Tyrosine Kinase Inhibitor-Induced Neuropathy.

Belair DG, Sudak K, Connelly K, Collins ND, Kopytek SJ, Kolaja KL. Belair DG, et al. Among authors: kolaja kl. Toxicol Sci. 2021 May 27;181(2):160-174. doi: 10.1093/toxsci/kfab033. Toxicol Sci. 2021. PMID: 33749749 Clinical Trial.

5

Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspective.

Pointon A, Maher J, Davis M, Baker T, Cichocki J, Ramsden D, Hale C, Kolaja KL, Levesque P, Sura R, Stresser DM, Gintant G. Pointon A, et al. Among authors: kolaja kl. Lab Chip. 2021 Feb 9;21(3):458-472. doi: 10.1039/d0lc01040e. Lab Chip. 2021. PMID: 33471007

6

Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs.

Belair DG, Visconti RJ, Hong M, Marella M, Peters MF, Scott CW, Kolaja KL. Belair DG, et al. Among authors: kolaja kl. Toxicol In Vitro. 2020 Oct;68:104928. doi: 10.1016/j.tiv.2020.104928. Epub 2020 Jul 3. Toxicol In Vitro. 2020. PMID: 32622998 Free article.

7

Developing in vitro assays to transform gastrointestinal safety assessment: potential for microphysiological systems.

Peters MF, Choy AL, Pin C, Leishman DJ, Moisan A, Ewart L, Guzzie-Peck PJ, Sura R, Keller DA, Scott CW, Kolaja KL. Peters MF, et al. Among authors: kolaja kl. Lab Chip. 2020 Apr 7;20(7):1177-1190. doi: 10.1039/c9lc01107b. Epub 2020 Mar 4. Lab Chip. 2020. PMID: 32129356 Review.

8

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.

Belair DG, Lu G, Waller LE, Gustin JA, Collins ND, Kolaja KL. Belair DG, et al. Among authors: kolaja kl. Sci Rep. 2020 Feb 18;10(1):2864. doi: 10.1038/s41598-020-59542-x. Sci Rep. 2020. PMID: 32071327 Free PMC article.

9

Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches.

Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Lamore SD, et al. Among authors: kolaja kl. Chem Res Toxicol. 2020 Jan 21;33(1):125-136. doi: 10.1021/acs.chemrestox.9b00387. Epub 2020 Jan 10. Chem Res Toxicol. 2020. PMID: 31840498 Review.

10

Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.

Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL. Peters MF, et al. Among authors: kolaja kl. Cardiovasc Toxicol. 2015 Apr;15(2):127-39. doi: 10.1007/s12012-014-9268-9. Cardiovasc Toxicol. 2015. PMID: 25134468 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters